Condition: Leukemia, Myeloid, Acute · Sponsor: Janssen Research & Development, LLC
The purpose of this study is to assess how bleximenib and Venetoclax (VEN)+ Azacitidine (AZA) works as compared to placebo and VEN+AZA alone for the treatment of participants with newly diagnosed Acute Myeloid Leukemia (AML) with a mutation in the NPM1 or KMT2A gene.
This description comes directly from the study's public registry record.
Study Contact · 844-434-4210 · Participate-In-This-Study1@its.jnj.com
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham | Birmingham, Alabama, United States | Recruiting |
| Cancer Treatment Center of America Phoenix | Goodyear, Arizona, United States | Recruiting |
| The University of Arizona Cancer Center | Tucson, Arizona, United States | Recruiting |
| University of Arkansas at Little Rock | Little Rock, Arkansas, United States | Recruiting |
| City of Hope | Duarte, California, United States | Recruiting |
| Rocky Mountain Cancer Centers | Aurora, Colorado, United States | Recruiting |
| Medical Oncology Hematology Consultants, PA | Newark, Delaware, United States | Recruiting |
| Florida Cancer Specialists & Research Institute | Fort Myers, Florida, United States | Recruiting |
| Jupiter Research | Jupiter, Florida, United States | Recruiting |
| Orlando Health Cancer Institute | Orlando, Florida, United States | Recruiting |
| Memorial Cancer Institute | Pembroke Pines, Florida, United States | Recruiting |
| Moffit Cancer center | Tampa, Florida, United States | Recruiting |
+ 241 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06852222